Search

Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease

Ready for the Challenge? Boehringer Ingelheim and Eli Lilly and Company Launch First Ever Online Game on Cardio-Renal-Metabolic Conditions for Healthcare Professionals

Full results from EMPERIAL exercise ability trials presented

Investigating MDM2-p53 in cancer

Our most advanced oncology asset in development is being clinically investigated as a potential treatment for people with dedifferentiated liposarcoma.

National Alliance for Hispanic Health Survey Provides Insights into Hispanic Attitudes Towards Diabetes

Results announced from EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial in adults following a heart attack.

New study results show Tradjenta® (linagliptin) reduces blood sugar in adults with type 2 diabetes at risk for kidney impairment

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Survey reveals healthcare professionals believe greater collaboration is needed to improve patient outcomes in diabetes care

FDA Approves Jardiance® (empaglifozin) for T2D | BI US

Read more about the approval of Boehringer Ingelheim's third product from the BI-Lilly Diabetes alliance, JARDIANCE, used to treat type-2 diabetes.

Positive results reported in HER2 mutated lung cancer

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

New type 2 diabetes treatment Jardiance® (empagliflozin) tablets for adults now available in U.S. pharmacies

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

Icahn School of Medicine at Mount Sinai and Boehringer Ingelheim collaborate on first study to evaluate nintedanib in patients with fibrosing ILD following COVID-19 infection

New retrospective data showed empagliflozin reduced A1C, body weight and markers of abdominal fat in adults with type 2 diabetes

Actress Angela Bassett joins For Your SweetHeart™ to urge people with diabetes to know their heart disease risk — in honor of her mom

U.S. FDA Approves Once-daily Jentadueto® XR (linagliptin and metformin hydrochloride extended-release) Tablets for Adults with Type 2 Diabetes

Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure

U.S. FDA grants Breakthrough Therapy designation for MASH

Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis

Jardiance® (empagliflozin) Shows Reduction in CV Risk & Death | Boehringer Ingelheim US

BI & Eli Lilly & Co.’s JARDIANCE reduced risk of CV death, non-fatal heart attack or non-fatal stroke by 14%. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) Tablets Studied in CKD | Boehringer Ingelheim US

BI & Eli Lilly & Co. announce plans for a new trial investigating JARDIANCE for the treatment of CKD. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) analysis reinforces established safety profile

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers